Novo Nordisk (NVO) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The AMAZE 6 trial, officially titled “Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Knee Osteoarthritis,” tests a new Novo Nordisk drug for weight loss and knee pain. It aims to show if once-weekly injections can safely help people lose weight and ease joint pain, which could open a new market segment for the company.
The study drug, NNC0487-0111, is a once-weekly injection given under the skin, similar in format to other modern weight-loss drugs. It is compared with a placebo injection and is used together with a low-calorie diet and more physical activity to see if it adds extra benefit beyond lifestyle changes.
The trial is a phase 3 interventional study with people randomly assigned to either NNC0487-0111 or placebo, which helps remove bias in the results. It uses a double-blind design where patients, doctors, and study staff do not know who gets which treatment, and the main goal is to test how well the drug treats excess weight and knee osteoarthritis.
The study was first submitted on 2026-03-29, marking the formal start of the trial process and regulatory tracking. The latest update was filed on 2026-05-13, which signals the protocol is active and still being refined as Novo Nordisk moves recruitment forward.
For investors, AMAZE 6 matters because it pushes Novo Nordisk into the overlap of obesity and osteoarthritis, a large and growing patient group. Positive data could support premium pricing and extend the weight-loss franchise beyond diabetes and obesity alone, strengthening NVO’s position versus rivals like Eli Lilly in the broader metabolic and musculoskeletal space.
The trial’s recruiting status means no top-line data yet, so near-term stock impact may be muted but it adds to the company’s long pipeline story. If later results show strong weight loss plus pain relief, this program could support long-term revenue and sustain investor confidence in Novo Nordisk’s innovation edge.
The AMAZE 6 study is currently ongoing and remains under active update, with further details available on the ClinicalTrials portal.
To learn more about NVO’s potential, visit the Novo Nordisk drug pipeline page.